A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 902-904

  Kumar, Anita ^a   Blum, Kristie A ^b   Fung, Henry C ^c   Smith, Mitchell R ^d   Foster, Paul A ^e   Younes, Anas ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e Xencor Inc   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Clinical trials; Hodgkin lymphoma; Immunotherapy; Monoclonal antibodies; Therapy

Indexed keywords

MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; XMAB 2513; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HODGKIN DISEASE; HUMAN; LETTER; MALE; MONOTHERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VOMITING; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; YOUNG ADULT;

EID: 84924083411     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13152     Document Type: Letter

References (8)

1. Ansell, S.M., Horwitz, S.M., Engert, A., Khan, K.D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A. & Borchmann, P. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Journal of Clinical Oncology, 25, 2764-2769.
2. Bartlett, N.L., Younes, A., Carabasi, M.H., Forero, A., Rosenblatt, J.D., Leonard, J.P., Bernstein, S.H., Bociek, R.G., Lorenz, J.M., Hart, B.W. & Barton, J. (2008) A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 + hematologic malignancies. Blood, 111, 1848-1854.
3. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
5. Forero-Torres, A., Leonard, J.P., Younes, A., Rosenblatt, J.D., Brice, P., Bartlett, N.L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, E.L. & Gopal, A.K. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British journal of haematology, 146, 171-179.
6. Hammond, PW, Vafa O, Jacinto, J, Vielmetter J, Karki, S, Yoder S, Lazar, G, Raturi D, Mollet, M, Zhu M, Kunkel, L & Carmichael D (2005) A humanized anti-CD30 monoclonal antibody, XmAb2513, with enhanced In vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annual Meeting Abstracts), 106, 1470.
7. Weng, W.K. & Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 3940-3947.
8. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L. & Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England Journal of Medicine, 363, 1812-1821.